411 related articles for article (PubMed ID: 35869066)
1. Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies.
Magalhães P; Lashuel HA
NPJ Parkinsons Dis; 2022 Jul; 8(1):93. PubMed ID: 35869066
[TBL] [Abstract][Full Text] [Related]
2. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies.
Moors TE; Mona D; Luehe S; Duran-Pacheco G; Spycher L; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Dernick G; van de Berg WDJ; Britschgi M
Acta Neuropathol Commun; 2022 Jun; 10(1):82. PubMed ID: 35659116
[TBL] [Abstract][Full Text] [Related]
3. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.
Lashuel HA
Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
5. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models.
Vinueza-Gavilanes R; Bravo-González JJ; Basurco L; Boncristiani C; Fernández-Irigoyen J; Santamaría E; Marcilla I; Pérez-Mediavilla A; Luquin MR; Vales A; González-Aseguinolaza G; Aymerich MS; Aragón T; Arrasate M
Neurobiol Dis; 2023 Jul; 183():106166. PubMed ID: 37245833
[TBL] [Abstract][Full Text] [Related]
6. Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight.
Al-Azzani M; König A; Outeiro TF
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204823
[TBL] [Abstract][Full Text] [Related]
7. Protein trapping leads to altered synaptic proteostasis in synucleinopathies.
Santos PI; Outeiro TF
FEBS J; 2020 Dec; 287(24):5294-5303. PubMed ID: 32400966
[TBL] [Abstract][Full Text] [Related]
8. Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies.
Brás IC; Outeiro TF
Cells; 2021 Feb; 10(2):. PubMed ID: 33673034
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of alpha-synuclein toxicity: An update and outlook.
Brás IC; Xylaki M; Outeiro TF
Prog Brain Res; 2020; 252():91-129. PubMed ID: 32247376
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of an aggregation-prone variant of alpha-synuclein used to model synucleinopathies.
Masaracchia C; König A; Valiente-Gabioud AA; Peralta P; Favretto F; Strohäker T; Lázaro DF; Zweckstetter M; Fernandez CO; Outeiro TF
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140298. PubMed ID: 31676453
[TBL] [Abstract][Full Text] [Related]
11. Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies.
Just MK; Gram H; Theologidis V; Jensen PH; Nilsson KPR; Lindgren M; Knudsen K; Borghammer P; Van Den Berge N
Front Aging Neurosci; 2022; 14():907293. PubMed ID: 35693346
[TBL] [Abstract][Full Text] [Related]
12. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities.
Visanji NP; Lang AE; Kovacs GG
Transl Neurodegener; 2019; 8():28. PubMed ID: 31508228
[TBL] [Abstract][Full Text] [Related]
13. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
14. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.
Schildknecht S; Gerding HR; Karreman C; Drescher M; Lashuel HA; Outeiro TF; Di Monte DA; Leist M
J Neurochem; 2013 May; 125(4):491-511. PubMed ID: 23452040
[TBL] [Abstract][Full Text] [Related]
15. Alpha Synuclein Connects the Gut-Brain Axis in Parkinson's Disease Patients - A View on Clinical Aspects, Cellular Pathology and Analytical Methodology.
Schaeffer E; Kluge A; Böttner M; Zunke F; Cossais F; Berg D; Arnold P
Front Cell Dev Biol; 2020; 8():573696. PubMed ID: 33015066
[TBL] [Abstract][Full Text] [Related]
16. PrP meets alpha-synuclein: Molecular mechanisms and implications for disease.
Vieira TCRG; Barros CA; Domingues R; Outeiro TF
J Neurochem; 2023 Oct; ():. PubMed ID: 37855859
[TBL] [Abstract][Full Text] [Related]
17. Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies.
Menon S; Armstrong S; Hamzeh A; Visanji NP; Sardi SP; Tandon A
Front Neurol; 2022; 13():852003. PubMed ID: 35614915
[TBL] [Abstract][Full Text] [Related]
18. Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions.
Jiménez-Jiménez FJ; Alonso-Navarro H; García-Martín E; Santos-García D; Martínez-Valbuena I; Agúndez JAG
Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627328
[TBL] [Abstract][Full Text] [Related]
19. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
[TBL] [Abstract][Full Text] [Related]
20. α-Synuclein Conformations in Plasma Distinguish Parkinson's Disease from Dementia with Lewy Bodies.
Kannarkat GT; Zack R; Skrinak RT; Morley JF; Davila-Rivera R; Arezoumandan S; Dorfmann K; Luk K; Wolk DA; Weintraub D; Tropea TF; Lee EB; Xie SX; Chandrasekaran G; Lee VM; Irwin D; Akhtar RS; Chen-Plotkin AS
bioRxiv; 2024 May; ():. PubMed ID: 38765963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
